大约70%的晚期乳腺癌为激素受体阳性HER2阴性，主要依靠内分泌治疗和化疗。对于内分泌治疗耐药患者，虽然细胞周期蛋白依赖性激酶CDK4/6抑制剂有效，但是仍然可能发生耐药。乳腺癌命运第四交响曲（DESTINY-Breast04）研究已经证实，德曲妥珠 ...

试验结果显示，在基线时存在脑转移的患者中，独立中央审评的12个月无进展生存率为61.6%。此外，脑转移患者的12个月颅内无进展生存率为58.9%。在脑转移稳定和活跃的患者中，结果一致。脑转移稳定患者的12个月无进展生存率为62.9%，颅内无进展生存率 ...

Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.

映恩生物在国内ADC领域的市场份额领先，特别是在HER2和B7-H3靶点的ADC药物开发上，具有全球领先的地位。公司的核心产品DB-1303/BNT323和DB-1311/BNT324在全球范围内的临床开发进度均处于行业前列。

上海浦东，最近杀出一个超级IPO：映恩生物。在癌症治疗领域，这是一家标准的超级隐形冠军。

Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...

9月13日晚间，恒瑞医药(600276)发布公告称，近日，公司子公司苏州盛迪亚生物医药有限公司收到国家药监局下发的《受理通知书》，公司注射用瑞康曲妥珠单抗（SHR-A1811）的药品上市许可申请获国家药监局受理，并且近日该产品已被纳入优先审评程序。

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Trastuzumab duocarmazine is under clinical development by Byondis and currently in Phase I for Metastatic Breast Cancer.

The DESTINY-Breast12 trial revealed that trastuzumab deruxtecan (T-DXd) effectively targets brain metastases in HER2-positive ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from the DESTINY-Breast12 Phase IIIb/IV trial showed that ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated substantial overall and intracranial ...